Ranolazine Dihydrochloride (CAS 95635-56-6)
See product citations (1)
QUICK LINKS
Ranolazine Dihydrochloride is a chemical that functions as an inhibitor of the late inward sodium current in cardiac cells. It exerts its mechanism of action by blocking the late sodium current in a use-dependent manner, which helps to reduce the intracellular sodium overload during ischemia and decrease the calcium overload. This inhibition of the late sodium current leads to a reduction in the excessive diastolic sodium-calcium exchange, thereby improving the diastolic function of the heart. Ranolazine Dihydrochloride have minimal effects on heart rate, blood pressure, and contractility, making it a suitable chemical for studying the modulation of cardiac ion channels and the impact on cellular electrophysiology. Its mechanism of action involves the direct interaction with the cardiac sodium channel, leading to a decrease in sodium influx during the action potential plateau phase. Ranolazine Dihydrochloride′s involves the investigation of its effects on cardiac electrophysiology and the potential for modulating ion channel activity in cardiac cells.
Ranolazine Dihydrochloride (CAS 95635-56-6) References
- Protective Effects of Ranolazine on Ventricular Fibrillation Induced by Activation of the ATP-Dependent Potassium Channel in the Rabbit Heart. | Gralinski, MR., et al. 1996. J Cardiovasc Pharmacol Ther. 1: 141-148. PMID: 10684411
- Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor. | Chaitman, BR. 2002. Curr Probl Cardiol. 27: 527-55. PMID: 12501118
- Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. | Sabbah, HN., et al. 2002. J Card Fail. 8: 416-22. PMID: 12528095
- The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice. | Suckow, MA., et al. 2004. Cancer Lett. 209: 165-9. PMID: 15159018
- Modelling the long QT syndrome with induced pluripotent stem cells. | Itzhaki, I., et al. 2011. Nature. 471: 225-9. PMID: 21240260
- Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. | Galimberti, ES. and Knollmann, BC. 2011. J Mol Cell Cardiol. 51: 760-8. PMID: 21798265
- Late cardiac sodium current can be assessed using automated patch-clamp. | Chevalier, M., et al. 2014. F1000Res. 3: 245. PMID: 25383189
- Ranolazine triggers pharmacological preconditioning and postconditioning in anesthetized rabbits through activation of RISK pathway. | Efentakis, P., et al. 2016. Eur J Pharmacol. 789: 431-438. PMID: 27492365
- In vivo characterization of anti-atrial fibrillatory potential and pharmacological safety profile of INa,L plus IKr inhibitor ranolazine using the halothane-anesthetized dogs. | Nunoi, Y., et al. 2021. Heart Vessels. 36: 1088-1097. PMID: 33763729
- Modulation of the effects of class Ib antiarrhythmics on cardiac NaV1.5-encoded channels by accessory NaVβ subunits. | Zhu, W., et al. 2021. JCI Insight. 6: PMID: 34156986
- Differentiating multichannel block on the guinea pig ECG: Use of Tpeak-Tend and J-Tpeak. | Skinner, M., et al. 2021. J Pharmacol Toxicol Methods. 111: 107085. PMID: 34182121
- Functional cross-talk between phosphorylation and disease-causing mutations in the cardiac sodium channel Nav1.5. | Galleano, I., et al. 2021. Proc Natl Acad Sci U S A. 118: PMID: 34373326
- Pharmacological characterisation of electrocardiogram J-Tpeak interval in conscious Guinea pigs. | Nogawa, H., et al. 2022. Eur J Pharmacol. 927: 175065. PMID: 35640715
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ranolazine Dihydrochloride, 100 mg | sc-205834 | 100 mg | $167.00 | |||
Ranolazine Dihydrochloride, 500 mg | sc-205834A | 500 mg | $615.00 |